sarclisa
sanofi winthrop industrie - isatuximab - mitu müeloomit - antineoplastilised ained - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.
zyrtec õhukese polümeerikattega tablett
ideal trade links uab - tsetirisiin - õhukese polümeerikattega tablett - 10mg 10tk; 10mg 30tk
zyrtec õhukese polümeerikattega tablett
ideal trade links uab - tsetirisiin - õhukese polümeerikattega tablett - 10mg 10tk; 10mg 30tk; 10mg 20tk
cetrix 10 mg õhukese polümeerikattega tablett
ideal trade links uab - tsetirisiin - õhukese polümeerikattega tablett - 10mg 20tk; 10mg 50tk; 10mg 10tk; 10mg 100tk
cetirizine pxgpharma õhukese polümeerikattega tablett
pxg pharma gmbh - tsetirisiin - õhukese polümeerikattega tablett - 10mg 21tk; 10mg 60tk; 10mg 90tk; 10mg 14tk; 10mg 50tk; 10mg 45tk; 10mg 1tk; 10mg 30tk; 10mg 10tk; 10mg 100tk; 10mg 20tk
spongostan spugna di gelatina emostatica riassorbibile
spongostan spugna di gelatina emostatica riassorbibile
spongostan polvere di gelatina emostatica riassorbibile
buvidal
camurus ab - buprenorfiini - opioidiga seotud häired - muud närvisüsteemi ravimid - opioidisõltuvuse ravi, mille raames meditsiinilise, sotsiaalse ja psühholoogilise ravi. ravi on mõeldud kasutamiseks täiskasvanutel ja noorukitel vanuses 16 aastat või üle.